欧盟拟拒绝授权阿斯利康疫苗出口至英国
外电引述欧盟高级官员消息指,欧盟可能拒绝阿斯利康(AZN.US)将新冠疫苗出口到英国的授权,以迫使该公司首先履行向欧盟交付的义务。
欧盟委员会主席冯德莱恩(Ursula von der Leyen)早前强调,阿斯利康原本承诺今年首季向欧盟供应9,000万剂疫苗,至今只交付30%,如果阿斯利康未能履行合约,可能禁止其疫苗出口。冯德莱恩又指,按照合约欧盟应获阿斯利康欧盟及英国工厂发货,但欧盟至今都未从英国取得疫苗,重申阿斯利康必须先履行与欧盟的合约,再向其他国家供货。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.